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A B S T R A C T
Left main coronary artery disease (LMCAD) is a special part of coronary pathology 
and its gold standard treatment is coronary artery bypass surgery (CABG). Over the 
last two decades, the evolution in technology and materials and the growing experi-
ence of interventional cardiologist treating acute coronary syndrome improved the re-
sults of percutaneous coronary interventions even in patients with LM disease. Recent 
prospective randomized studies though (SYNTAX) as well as large registries com-
paring the two methods showed comparable results concerning safety and inferiority 
of PCI regarding restenosis and need for reintervention. Up to now CABG remains 
the treatment of choice for LM disease with PCI being a reliable alternative solution 
in cases of patients of high surgical risk. The above is strongly recommended by the 
new guidelines.
I N T R O D U C T I O N
Cardiovascular disease is by far the first cause of death in the western world. The 
prevention and the reduction of cardiac risk factors have beneficial results in the general 
population, moving the main problem to more elder group of people.
Coronary-artery bypass grafting (CABG) was introduced in 1968 and rapidly 
became the standard of care for symptomatic patients with coronary artery disease.1 
Advances in coronary surgery (e.g., off-pump CABG, smaller incisions, enhanced 
myocardial preservation, use of arterial conduits, improved postoperative care as well 
as widely published surgical outcomes) have reduced morbidity, mortality, and rates 
of graft occlusion.2-4 The rate of mortality at a global level is less than 2% and in most 
recent studies it is less than 1.3%, including emergency and complex cases.
The incidence of left main (LM) coronary artery disease (LMCAD) among patients 
undergoing coronary angiography ranges from 4% to 6%.5 The same percentage for 
those undergoing surgery is as much as 30%. Although uncommon, LMCAD is a 
constant topic of discussion between cardiac surgeons and interventional cardiologists. 
This discussion began in 1975, when Gorlin and Cohen6 first compared a surgical 
approach for LM stenosis to any other treatment option and reported that CABG 
showed significant benefits.
Since then and for over 45 years researchers are trying to find alternative and less 
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interventional methods to treat LMCAD. Thus, almost one 
decade following the first CABG (1977), the percutaneous 
coronary intervention (PCI) with the use of plain balloon 
angioplasty was first introduced and then there followed the 
introduction of bare metal stents (BMS), which significantly 
reduced the restenosis rate of plain angioplasty.7 This par-
ticular method, coupled with improved technology, has made 
it possible to treat increasingly complex lesions and patients 
with a history of clinically significant cardiac disease, risk fac-
tors for coronary artery disease (CAD), coexisting conditions, 
or anatomical risk factors.8,9 Still, however, the high rates of 
mortality and restenosis with the use of BMS in the case of 
LM disease led the American Heart Association – AHA, the 
American College of Cardiology – ACC and the European 
Society of Cardiology – ESC to announce strict guidelines 
confirming CABG as the treatment of choice for LM CAD.10-13 
The percutaneous method with use of BMS was given a class 
III designation for this particular subgroup and was made 
available only to patients disqualified from all other possible 
methods of treatment.
Nevertheless, over the last several years, with improved 
PCI methods, use of adjunctive medical therapy and the 
development of new stent design with the drug-eluting stents 
(DES), which have significantly curtailed the restenosis rate, 
PCI has emerged as a possible alternative in patients with 
complex coronary disease.9,14 Recent revisions to revasculari-
zation guidelines have reflected these improvements in PCI 
outcomes for patients with complex coronary disease.15,16 In 
general, during the first year after the index procedure, PCI 
has been found to be as safe as CABG in patients with severe 
coronary artery disease; however, the rates of recurrences 
are significantly higher and PCI has again failed to show non-
inferiority compared with CABG due to increased need for 
repeat revascularization.17,18
New randomized trials with large series of patients, like 
the SYNTAX trial (SYNergy Between PCI with TAXUS 
and Cardiac Surgery), try to clarify the advantages and dis-
advantages of the two methods. The results of these studies 
will possibly answer the question whether modern PCI with 
DES can compete with CABG in the treatment of LMCAD 
concerning safety and long-term results.
G E N E R A L  S T A T E M E N T
Before proceeding to the analysis of the recent data about 
PCI and CABG, it would be proper to make the following 
statements:
 1. Patients prefer less interventional therapies
 2. The proper and well documented use of PCI can be a use-
ful tool in the management of coronary artery disease. For 
example, the advantages of PCI in the treatment of acute 
coronary syndrome are undoubtful.
L E F T  M A I N  C O R O N A R Y  A R T E R Y 
D I S E A S E  ( L M C A D )  –  C U R R E N T 
P E R S P E C T I V E S
Left main CAD is part of the pathology in 4-6%19 of the 
patients undergoing PCI and in almost 30%20 of the patients 
undergoing CABG. Although CABG is the gold standard 
treatment for LMCAD, according to all major cardiology 
societies,10-13 29% of the patients with LMCAD in Europe 
and 18% in North America are still being treated with PCI.21
The large size of the left main coronary artery renders it 
an “attractive” site for the use of endovascular stents when 
compared with the other coronary arteries. Nevertheless there 
are two anatomical elements because of which PCI cannot 
guarantee long term results: 1) Almost 90% of the lesion of the 
LM involves its bifurcation or its distal segment,22-24 sites which 
present high rates of restenosis,25 2) 80% of the patients with 
LMCAD have additional multiple lesions in other coronary 
arteries.22-24 In these cases the treatment is obviously surgical.
Serruys et al give emphasis to the significance of distal 
lesions in the LM coronary artery and their role in the appear-
ance of major adverse cardiovascular or cerebrovascular events 
(MACCE) shortly after PCI is performed. Their study revealed 
a 30% rate of MACCE in patients with distal stenosis, whereas 
only 11% of the patients without distal stenosis suffered from 
MACCE. It must be pointed out that the procedures in this 
study were performed by one of the most experienced team 
of interventional cardiologists.25
The outcome of the use of BMS was not satisfactory in the 
treatment of LMCAD. The analysis of the results of 8 studies 
performed in the period between 1999 and 2003 concerning 
1100 patients showed in-hospital mortality of 6%, need for 
repeat revascularization 0-20% and 2-year mortality 17%.26 
The results were better in young patients with good ventricular 
function and lesion in the middle segment of LM coronary 
artery. The 3-year mortality in this group was 7.4%.27-29 On 
the other hand the results of CABG in low risk patients are 
excellent. For example in the SOS study the mortality rate 
after 1 year follow-up was 0.8%.
Drug eluting stents (DESs) were expected to be the solu-
tion to the problem of restenosis of BMS and therefore their 
use, even in cases with LM disease, started to expand.22-24 
Studies with DES showed impressive results reaching 2% 
in-hospital mortality rate and 2% need for urgent repeat 
revascularization. Nevertheless all these studies were badly 
designed and included a small sample of patients (50-130) 
and also had a small period of follow-up (in most studies less 
than one year). Price et al. conducted the only study with an-
giographic examination for restenosis at 3 and 9 months after 
PCI and found rates of restenosis 34% and 44% respectively.24
The need for a large scale randomized study comparing 
PCI and CABG led to the design of the SYNTAX trial. The 
148
HOSPITAL CHRONICLES 2010, VOLUME 7, SUPPLEMENT 1: «ATHENS CARDIOLOGY UPDATE 2012»
purpose of this trial was to determine whether or not the PCI 
method using DES (Taxus Express 2, Boston Scientific) has 
comparable safety rates and success with CABG in patients 
with three vessel disease (3VD) or LM disease.
The results of the SYNTAX trial after 1 year of follow-up 
revealed that the major cardiovascular and cerebrovascular 
events (MACCE) were more frequent in the PCI group than 
in the CABG group but with no significant difference (15.8% 
vs. 13.7% respectively, p=0.44). The major difference among 
the two groups concerning MACCE was detected in the rate 
of repeat revascularization, where the PCI group had almost 
double percentage in comparison with the CABG group (6.5% 
vs. 11.8% respectively, p=0.02). Angioplasty was found to be 
as safe as the surgical treatment and with comparable rates 
of mortality. On the other hand, the CABG group had signifi-
cantly greater incidence of stroke comparing to the PCI group 
(2.7% vs. 0.3% respectively, p=0.01)18 (Figure 1).
The above results were confirmed and further emphasized 
by the analysis of the data after a 3-year follow-up period 
and even more recently in the 4-year follow-up report. More 
specifically in the LM cohort, the rates of MACCE and death/
stroke/myocardial infarction (MI) were not significantly dif-
ferent in PCI- and CABG-treated patients. The 3-year rate 
of repeat revascularization was increased in PCI-treated LM 
patients (20% vs. 11.7% respectively, p=0.004). There was 
no difference in all-cause or cardiac death rates in CABG- or 
PCI-treated patients with LM disease (all-cause: CABG 8.4% 
vs. PCI 7.3%, p=0.64; cardiac death 4.6 vs. 5.7%, p=0.48)30 
(Figure 2).
It must be pointed out that the results described here are 
only a part of the SYNTAX trial and have to do only with the 
subgroup of patients suffering from LM disease. The rates 
FIGURE 1. Rates of outcomes among the patients (3VD and LM subgroups), according to treatment – 1 year follow-up of “SYN-
TAX trial”. Kaplan–Meier curves are shown for the percutaneous coronary intervention (PCI) group and the coronary-artery bypass 
grafting (CABG) group for repeat revascularization (Panel A); and the composite primary end point of major adverse cardiac or 
cerebrovascular events (Panel B). The rate of repeat revascularization was significantly increased with PCI (relative risk, 2.29; 95% 
CI, 1.67 to 3.14), as was the overall rate of major adverse cardiac or cerebrovascular events (relative risk, 1.44; 95% CI, 1.15 to 1.81). 
P values were calculated with the use of the chi-square test. (N Engl J Med, 2009.360, 10: 961-972, Modified).
FIGURE 2. Three-year clinical outcomes according to the treatment group in patients with left main disease – 3 year follow-up 
of “SYNTAX trial”. Death/stroke/myocardial infarction, all-cause death, stroke, myocardial infarction, repeat revascularization (re-
peat revasc), and major adverse cardiac and cerebrovascular event rates at 3 years in coronary artery bypass grafting (blue bars) or 
percutaneous coronary intervention-treated (yellow bars). P-value from log-rank test. (Eur Heart J, 2011. 32: 2125-2134, Modified).
CABG FOR LEFT MAIN CORONARY DISEASE
149
of three-year clinical outcomes in the overall randomized 
cohort (LM and 3 vessel subgroups together) were even more 
favorable for those who underwent surgery concerning cardiac 
death, stroke, MI, revascularization and MACCE30 (Figure 3).
Furthermore the SYNTAX trial introduced a helpful 
“tool”, the “SYNTAX score”, which was designed to predict 
outcomes related to anatomical characteristics and, to a lesser 
extent, the functional risk of occlusion for any segment of 
the coronary-artery bed (as reflected by the Leaman score31). 
The Syntax score is calculated with the use of a complicated 
algorithm which takes into account the vascular dominance, 
the number, the length and the topography of the lesions, the 
presence of total occlusion, the existence and the type of bi- or 
trifurcations, the presence or not of endovascular thrombus, 
the morphology of the coronary vessels and the severity of the 
calcifications. When the population of the study was divided 
into three subgroups according to the SYNTAX score (low – 
0-22, intermediate – 23-32 or high – ≥33), the LM patients with 
the most complex anatomy who were treated with PCI were 
found to have significantly increased incidence of MACCE 
(CABG 21.2% vs. PCI 37.3%, p=0.003) and need for repeat 
revascularization (CABG 9.2% vs. PCI 27.7%, p<0.001) 
(Figure 4).
Taking all the above data under consideration, the current 
US and European revascularization guidelines assign CABG 
a IA indication in most patients with 1, 2, or 3VD with low, 
intermediate, or high SYNTAX scores.15,32 However, due to 
positive outcomes from other recent studies of LM patients, 
these guidelines have upgraded the indication for PCI in the 
LM artery from a Class III to a Class IIb (ACC/AHA)15,32 and 
a Class IIb C to IIa B (ESC-EACTS) 33] indication in patients 
with isolated LM (ostial or trunk) and with associated 1 vessel 
disease. Additionally, the ESC-EACTS guidelines have also 
included the treatment of patients with 3VD and low SYNTAX 
scores as a Class IIa B indication33 (Figure 5).
Moreover the use of the SYNTAX score revealed that 
surgical revascularization remains the standard treatment for 
patients with more complex coronary anatomy, whereas PCI 
demonstrates similar outcomes when compared to CABG in 
patients with less complex disease and lower SYNTAX score 
for 3VD and lower and intermediate scores for LM disease. 
Retrospective application of the SYNTAX score to other pa-
tient groups has shown value in predicting or correlating high 
anatomical complexity with increased adverse cardiac events 
making it an effective risk assessment tool.34-37
D E B A T E  B E T W E E N  C A R D I A C  S U R G E O N 
A N D  I N T E R V E N T I O N A L  C A R D I O L O G I S T
The modern surgeons, after studying all the results 
from the latest trials and combining them with their experi-
ence, reached the conclusion that CABG is the treatment 
of choice for patients with LM disease and especially for 
those with complicated stenosis (high SYNTAX score). In 
this group of people, PCI failed to present similar results 
FIGURE 3. Rates of clinical outcomes among randomized treatment groups – 3 year follow-up of “SYNTAX trial”. Three-year 
clinical outcomes in coronary artery bypass grafting (blue bars) or percutaneous coronary intervention (yellow bars). Repeat revas-
cularization is broken down into repeat percutaneous coronary intervention (yellow or blue bars) and repeat coronary artery bypass 
grafting (striped yellow or blue bars). The Kaplan–Meier event rates, P-value from log-rank test. (Eur Heart J, 2011. 32: 2125-2134, 
Modified).
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FIGURE 5. ESC-EACTS guidelines. Indications for coronary bypass grafting vs. PCI in patients with lesions suitable for both proce-
dures and low predicted surgical mortality.
FIGURE 4. Major adverse cardiac and cerebrovascular event rates according to the subset, treatment group, and SYNTAX score 
category – 3 year follow-up of “SYNTAX trial”. Time-to-event curves in the coronary artery bypass grafting (blue line) or percuta-
neous coronary intervention (yellow line) overall cohorts to 3 years according to the low (0–22), intermediate (23–32), or high (≥33) 
SYNTAX scores. Major adverse cardiac and cerebrovascular events in patients with left main disease with low, intermediate, or high 
SYNTAX scores. P-value from log-rank test. (Eur Heart J, 2011. 32: 2125-2134, Modified).
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concerning MACCE incidence. Additionally, more than 1/3 
of the patients with LM disease seeking medical help are 
characterized unsuitable for PCI treatment from the begin-
ning. This fact on its own indicates that CABG remains the 
best way to deal with complex coronary and LM disease. 
It is associated with a relatively low mortality and clearly 
lesser need for re-intervention. Should this rare necessity 
occur, reintervention is almost absolutely a safe PCI as 
opposed to surgical reintervention following PCI which is 
of a higher risk procedure.
On the other hand, interventional cardiologists still be-
lieve that PCI is a reliable solution for managing coronary 
disease even in some cases of LM disease. This opinion 
is based on the fact that PCI is not an inferior method 
compared to CABG when taking under consideration the 
overall mortality rates and MACCE incidences apart from 
repeat revascularization. Moreover the convenience of the 
method for the patient, the fewer days the patient has to 
stay in the hospital, the faster recovery and the ability to be 
performed on emergency basis are some arguments in favor 
of PCI with the use of DES, especially for elderly people 
(octogenarians) and patients with other co-morbidities and 
a high surgical risk (high EUROscore).
In addition, it should be emphasized that more com-
plete information about the patient’s clinical and angio-
graphic profile and comorbidities is warranted, while the 
patient and family should also be fully informed about the 
available options and the associated procedural risks and 
benefits; finally, publication of procedure outcomes should 
be mandated for either team, as it is already done by the 
surgeons in several US states.
C O N C L U S I O N
After taking all the above under consideration we can reach 
the conclusion that CABG remains the treatment of choice 
for patients with complex coronary disease (3VD patients 
with intermediate/high SYNTAX scores and LM patients with 
high scores) because they seem to have an increased risk of a 
MACCE event when treated with the PCI method. Patients 
with less complex coronary anatomy (low SYNTAX scores 
in 3VD patients or low/intermediate SYNTAX scores in LM 
patients) can be alternatively treated with PCI, but CABG 
remains the preferred treatment option in this last cohort of 
patients.
In closing we must say that the decision for the appropriate 
treatment for the patient should be the outcome of the close 
and impartial cooperation of interventional cardiologist and 
cardiac surgeon. The goal of this cooperation should be only 
the best interest of the patient and in cases of disagreement 
the patient himself should take the decision after being fully 
informed by the medical team.
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